Published in J Cell Mol Med on August 01, 2011
Novel classes of non-coding RNAs and cancer. J Transl Med (2012) 1.35
NF-кB-regulated micro RNAs (miRNAs) in primary human brain cells. Exp Neurol (2011) 1.26
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol (2013) 1.20
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol (2012) 1.14
MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. RNA (2013) 1.06
MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals (Basel) (2013) 1.04
Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci (2014) 1.02
Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells. Oncol Lett (2013) 1.01
MicroRNA-377 inhibited proliferation and invasion of human glioblastoma cells by directly targeting specificity protein 1. Neuro Oncol (2014) 0.99
Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human glioma. J Pathol (2013) 0.96
Clinical implications of microRNAs in human glioblastoma. Front Oncol (2013) 0.88
A microRNA Link to Glioblastoma Heterogeneity. Cancers (Basel) (2012) 0.80
High-grade glioma in elderly patients: can the oncogeriatrician help? Clin Interv Aging (2013) 0.79
Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p. Neuro Oncol (2015) 0.78
Role of MicroRNAs in Malignant Glioma. Chin Med J (Engl) (2015) 0.77
Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther (2016) 0.75
MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras. Am J Cancer Res (2017) 0.75
On-Chip Clonal Analysis of Glioma-Stem-Cell Motility and Therapy Resistance. Nano Lett (2016) 0.75
MicroRNA-625 inhibits the proliferation and increases the chemosensitivity of glioma by directly targeting AKT2. Am J Cancer Res (2017) 0.75
Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer (2007) 3.16
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 2.57
Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev (2012) 2.47
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst (2002) 1.77
Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep (2006) 1.70
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med (2012) 1.62
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun (2009) 1.45
Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs (2012) 1.44
Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res (2010) 1.36
Novel classes of non-coding RNAs and cancer. J Transl Med (2012) 1.35
Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med (2012) 1.34
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci (2011) 1.28
Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer (2012) 1.26
Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med (2012) 1.24
Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica (2013) 1.22
Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol (2008) 1.21
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol (2012) 1.16
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol (2012) 1.14
MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. J Neurooncol (2013) 1.14
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol (2012) 1.11
Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol (2007) 1.09
MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol (2012) 1.08
Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol (2013) 1.08
microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol (2010) 1.07
A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res (2012) 1.04
MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun (2011) 1.01
Numerical defects in CD8+CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol (2010) 1.00
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol (2012) 1.00
Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark (2012) 0.98
Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology (2011) 0.97
Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol (2008) 0.97
MicroRNAs involved in chemo- and radioresistance of high-grade gliomas. Tumour Biol (2013) 0.96
Triterpenoid pyrazines and benzopyrazines with cytotoxic activity. J Nat Prod (2007) 0.95
Dumbbell-shaped peripheral primitive neuroectodermal tumor of the spine--case report and review of the literature. J Neurooncol (2008) 0.93
Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2008) 0.93
Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res (2008) 0.92
Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis. Cell Transplant (2015) 0.91
Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? J Neuroimmunol (2010) 0.91
MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol (2013) 0.91
Synthesis of A-seco derivatives of betulinic acid with cytotoxic activity. J Nat Prod (2004) 0.91
Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis (2012) 0.90
Small nucleolar RNAs functioning and potential roles in cancer. Tumour Biol (2014) 0.89
Intramedullary spinal cord and cauda equina metastasis of breast carcinoma: case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2010) 0.89
Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma (2012) 0.88
Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population. Eur J Med Res (2012) 0.88
Synthesis of phthalates of betulinic acid and betulin with cytotoxic activity. Bioorg Med Chem (2005) 0.87
Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc Toxicol (2012) 0.87
Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy. J Cell Mol Med (2012) 0.86
Generalization of DNA microarray dispersion properties: microarray equivalent of t-distribution. Biol Direct (2006) 0.86
Non-small cell lung cancer--genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2013) 0.86
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2010) 0.86
Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2009) 0.85
Analysis of state-specific phosphorylation of proteins by two-dimensional gel electrophoresis approach. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.85
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int J Oncol (2012) 0.84
Human myeloid dendritic cells for cancer therapy: does maturation matter? Vaccine (2010) 0.84
HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma. Diagn Pathol (2012) 0.84
The role of microRNAs in mitochondria in cancer. Cancer Lett (2013) 0.84
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumour Biol (2015) 0.83
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol (2014) 0.83
Therapeutic dendritic cell-based cancer vaccines: the state of the art. Crit Rev Immunol (2013) 0.83
Modeling effect of the septic condition and trauma on C-reactive protein levels in children with sepsis: a retrospective study. Crit Care (2007) 0.83
Characterization of pseudacyclins A-E, a suite of cyclic peptides produced by Pseudallescheria boydii. J Nat Prod (2010) 0.83
Dendritic cells and their role in tumor immunosurveillance. Innate Immun (2012) 0.83
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Support Care Cancer (2005) 0.83
Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs. Cancer Biother Radiopharm (2010) 0.83
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. Eur J Pediatr (2005) 0.83
Cytotoxic heterocyclic triterpenoids derived from betulin and betulinic acid. Bioorg Med Chem (2012) 0.82
Fenretinide prevents inflammation and airway hyperresponsiveness in a mouse model of allergic asthma. Am J Respir Cell Mol Biol (2014) 0.82
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82
Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application. J Proteome Res (2010) 0.82
Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy. J Proteome Res (2012) 0.82
Cancer cell response to anthracyclines effects: mysteries of the hidden proteins associated with these drugs. Int J Mol Sci (2012) 0.81
Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J Neurol Sci (2012) 0.81
Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy. Med Sci Monit (2009) 0.81
Evaluation of laparoscopic resection of colorectal carcinoma from the viewpoint of molecular biology. Wideochir Inne Tech Maloinwazyjne (2011) 0.81